Compare Jabil Inc (JBL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Natera Inc. Common Stock — how do they compare? Jabil Inc trades at $290 (market cap $33.31B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Jabil Inc pays a 0.1% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 24 Days and Natera Inc. Common Stock for 0 Days on average.
| JBL | NTRA | |
|---|---|---|
Market Cap | $33.31B | $57.03B |
Volume | 1,264,382 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $385.50 | $425.64 |
52-Week Low | $192.49 | $179.42 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $35.59B | $56.18B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $317.86, up 1.87% with strong technical momentum and bullish moving averages. The company delivered three consecutive earnings beats, with Q2 2026 EPS of $4.40 beating expectations of $4.07. Revenue growth is accelerating, with fiscal 2027 guidance projecting 24% growth driven by AI infrastructure demand. Analyst consensus remains strongly bullish with a $434.75 price target representing 37% upside potential.
The outlook remains positive with AI-driven growth catalysts and strong institutional support, though risks include execution challenges in scaling operations and market volatility despite strong fundamentals. Current valuation at 32.6 P/E appears reasonable given the growth trajectory, while the 74.11% ROE demonstrates exceptional capital efficiency.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
